GlassScriptPhysician profile
New Sang
NPI 1154340586
$1,393.17
in general payments reported to CMS, 2019-2025
20 companies · $434 in 2025
The $434 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.04 · 2020: $47.88 · 2021: $114 · 2022: $193 · 2023: $423 · 2024: $115 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $227.11 | 2019-2025 | Bexsero, Pediarix |
| Cranial Technologies, INC | $203.18 | 2020-2024 | Doc Band |
| Regeneron Healthcare Solutions, INC. | $165.07 | 2024-2025 | Dupixent |
| Verrica Pharmaceuticals INC. | $149.68 | 2023-2024 | Ycanth |
| Medline Industries LP | $95.89 | 2025 | |
| Sanofi Pasteur INC. | $75.96 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $70.61 | 2025 | Jornay Pm |
| Phadia US INC. | $65.82 | 2023 | Immunocap |
| Nestle Healthcare Nutrition INC. | $44.71 | 2022-2023 | |
| Pfizer INC. | $40.94 | 2023 | |
| Sobi, INC | $37.28 | 2021-2022 | |
| Abbott Laboratories | $37.00 | 2023 | Id Now Instrument |
| Sanofi-Aventis U.S. LLC | $35.20 | 2024-2025 | |
| Seqirus USA INC | $31.18 | 2022-2025 | Flucelvax |
| Merck Sharp & Dohme LLC | $20.89 | 2025 | Vaxelis, Vaxneuvance, Enflonsia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $20.23 | 2025 | Zelsuvmi |
| Supernus Pharmaceuticals, INC. | $18.90 | 2021 | |
| Acadia Pharmaceuticals INC | $18.88 | 2023 | Daybue |
| Ironshore Pharmaceuticals INC. | $17.58 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.06 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw New Sang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.